Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozymeâs recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.
Original Article: Genentech taps Halozyme’s tech in Herceptin Hylecta